Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.42 USD | +5.70% | +20.45% | -17.46% |
Financials (USD)
Sales 2024 * | 223M | Sales 2025 * | 321M | Capitalization | 565M |
---|---|---|---|---|---|
Net income 2024 * | -281M | Net income 2025 * | -151M | EV / Sales 2024 * | 3.03 x |
Net Debt 2024 * | 112M | Net Debt 2025 * | 118M | EV / Sales 2025 * | 2.13 x |
P/E ratio 2024 * |
-2.16
x | P/E ratio 2025 * |
-4.37
x | Employees | 380 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.25% |
Latest transcript on Travere Therapeutics, Inc.
1 day | +5.70% | ||
1 week | +20.45% | ||
1 month | +34.18% | ||
3 months | -1.85% | ||
6 months | +18.15% | ||
Current year | -17.46% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 51 | 19-01-03 |
Chris Cline
DFI | Director of Finance/CFO | 40 | 14-07-31 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 49 | 22-01-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Coughlin
BRD | Director/Board Member | 57 | 15-03-30 |
Jeffrey Meckler
BRD | Director/Board Member | 57 | 14-10-07 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 20-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - | |
0.06% | 1,487 M€ | +7.77% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 7.42 | +5.70% | 1,099,004 |
24-05-30 | 7.02 | +2.63% | 1,073,788 |
24-05-29 | 6.84 | +1.18% | 1,033,376 |
24-05-28 | 6.76 | +9.74% | 1,323,770 |
24-05-24 | 6.16 | -2.84% | 591,865 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.46% | 565M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- TVTX Stock